Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics and WuXi Vaccines Sponsor “100K in 30 Days” for Ireland Charity
Jul. 29, 2022
WuXi Biologics and WuXi Vaccines Sponsor “100K in 30 Days” for Ireland Charity

Dundalk, Ireland, July 29, 2022 – WuXi Biologics and WuXi Vaccines recently once again sponsored “100K in 30 Days” in aid of a charity organization, Breast Cancer Ireland. More than 200 employees volunteered to participate.

 

The “100K in 30 Days” fundraiser origins in Blackrock, a town within 10 mins drive from WuXi Biologics Dundalk site. Launched for Breast Cancer Ireland, the fundraiser initiative attracts more than 10,000 participants every year and is now one of the most influential charity events in Ireland. It is the second year that WuXi Biologics and WuXi Vaccines become major sponsors of the event, to help call for supporting breast cancer patients.

 

 

Recently, over 200 employees including Dr. Chris Chen, CEO of WuXi Biologics, joined the lunchtime walk cross the month at Dundalk site, among which over 120 completed the 100km challenge.

 

 

Dr. Chris Chen said at the event site, “We are delighted to sponsor and participate in the ‘100K in 30 Days’ initiative in two consecutive years as a trusted community contributor. WuXi Biologics views corporate social responsibility as a significant element of the company’s overall strategy for supporting sustainable development. The company is enabling partners to accelerate multiple novel biologics treating various diseases including cancers, benefiting patients worldwide. It is a meaningful initiative that echoes with our vision ‘Every drug can be made and every disease can be treated.’”

 

WuXi Biologics has long practiced corporate social responsibility by both leveraging the company’s strength to benefit patients and empowering employees’ volunteerism and social responsibility. Over the past decade, WuXi Biologics has been leveraging its technology platforms and professional insights to enable global partners to accelerate the R&D of innovative biological drugs that can treat cancers
to benefit patients worldwide. The company also established a volunteer association to promote well organized and sustainable activities, as well as organizes regular activities and encourage staff to participate, support public welfare through practical action, and shoulder social responsibility together. In recent years, employees from nine cities in four countries contributed to volunteer initiatives covering public health, environmental protection and youth education.

 

About WuXi Vaccines

 

WuXi Vaccines is a joint venture between WuXi Biologics (Stock Code: 2269.HK) and Shanghai Hile Bio-Technology (Stock Code: 603718.SH). Through its world-class integrated platforms, WuXi Vaccines offers end-to-end solutions for global partners to discover, develop and manufacture vaccines (including cancer vaccines) from concept to commercial manufacturing. WuXi Vaccines signed a 20-year vaccine manufacturing contract valued at approximately $3 billion USD with a global pharmaceutical company. To implement this landmark agreement, WuXi Vaccines is building a vaccine manufacturing facility in Dundalk, Ireland, where it has completed weather-tight construction of the site’s main building and begun operations in a newly built QC potency lab. For more information, please visit www.wuxibiologics.com/wuxi-vaccines.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a global leading Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of April 30, 2022, WuXi Biologics is supporting 526 integrated client projects, including nine in commercial manufacturing.

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, further enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

Media

PR@wuxibiologics.com

 

ESG

ESG@wuxibiologics.com

 

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?